Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development
Authors
Keywords
-
Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 51, Issue 35, Pages 8708-8720
Publisher
Wiley
Online
2012-06-19
DOI
10.1002/anie.201201616
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
- (2012) Eva M. Huber et al. CELL
- Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
- (2012) Alexei F. Kisselev et al. CHEMISTRY & BIOLOGY
- The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
- (2012) Kenneth C. Anderson JOURNAL OF CLINICAL ONCOLOGY
- Hydroxyureas as Noncovalent Proteasome Inhibitors
- (2011) Nerea Gallastegui et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
- (2011) H. Travis Ichikawa et al. ARTHRITIS AND RHEUMATISM
- Exploiting nature's rich source of proteasome inhibitors as starting points in drug development
- (2011) Melissa Ann Gräwert et al. CHEMICAL COMMUNICATIONS
- Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib
- (2011) Anne C. Mirabella et al. CHEMISTRY & BIOLOGY
- Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer
- (2011) S. M. Molineaux CLINICAL CANCER RESEARCH
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
- (2011) D. J. Kuhn et al. CURRENT CANCER DRUG TARGETS
- Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
- (2011) B. C. Potts et al. CURRENT CANCER DRUG TARGETS
- Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
- (2011) Michael Groll et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- The Immunoproteasome: An Emerging Therapeutic Target
- (2011) Wooin Lee et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- The Antiviral Immune Response in Mice Devoid of Immunoproteasome Activity
- (2011) M. Basler et al. JOURNAL OF IMMUNOLOGY
- Novel Proteasome Inhibitors to Overcome Bortezomib Resistance
- (2011) Amy M. Ruschak et al. JNCI-Journal of the National Cancer Institute
- Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells
- (2011) N E Franke et al. LEUKEMIA
- Mice completely lacking immunoproteasomes show major changes in antigen presentation
- (2011) Eleanor Z Kincaid et al. NATURE IMMUNOLOGY
- Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells
- (2011) Erika Suzuki et al. PLoS One
- Elucidation of the α-Keto-Aldehyde Binding Mechanism: A Lead Structure Motif for Proteasome Inhibition
- (2010) Melissa Ann Gräwert et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit
- (2010) Christopher Blackburn et al. BIOCHEMICAL JOURNAL
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
- (2010) D. Chauhan et al. BLOOD
- PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
- (2010) Ajita V. Singh et al. BRITISH JOURNAL OF HAEMATOLOGY
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress
- (2010) Ulrike Seifert et al. CELL
- 20S Proteasome Inhibition: Designing Noncovalent Linear Peptide Mimics of the Natural Product TMC-95A
- (2010) Michael Groll et al. ChemMedChem
- Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
- (2010) E. Genin et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
- (2010) Lawrence R. Dick et al. DRUG DISCOVERY TODAY
- Nature of Pharmacophore Influences Active Site Specificity of Proteasome Inhibitors
- (2010) Michael Screen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome
- (2010) M. Basler et al. JOURNAL OF IMMUNOLOGY
- Molecular Basis of the Selectivity of the Immunoproteasome Catalytic Subunit LMP2-Specific Inhibitor Revealed by Molecular Modeling and Dynamics Simulations
- (2010) Beilei Lei et al. JOURNAL OF PHYSICAL CHEMISTRY B
- Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma
- (2010) Paul G Richardson LANCET ONCOLOGY
- Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
- (2010) M Ri et al. LEUKEMIA
- Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies
- (2010) Guido Cavaletti et al. LEUKEMIA & LYMPHOMA
- Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
- (2009) Daniel Finley Annual Review of Biochemistry
- Cardiovascular Inflammation and Lesion Cell Apoptosis
- (2009) Zhaoqing Yang et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
- (2009) F. Parlati et al. BLOOD
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
- (2009) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents
- (2009) Takashi Takeshita et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites
- (2009) Matthew Britton et al. CHEMISTRY & BIOLOGY
- Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line
- (2009) Shuqing Lü et al. EXPERIMENTAL HEMATOLOGY
- Expression of catalytic proteasome subunits in the gut of patients with Crohn’s disease
- (2009) Alexander Visekruna et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Function-Oriented Biosynthesis of β-Lactone Proteasome Inhibitors inSalinispora tropica
- (2009) Markus Nett et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
- (2009) Han-Jie Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
- (2009) D Gutman et al. LEUKEMIA
- Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)
- (2009) Tianhong Li et al. LUNG CANCER
- A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
- (2009) Tony Muchamuel et al. NATURE MEDICINE
- Many facets of bortezomib resistance/susceptibility
- (2008) S. Kumar et al. BLOOD
- Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
- (2008) Deborah J. Kuhn et al. BLOOD
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- Argyrin A Reveals a Critical Role for the Tumor Suppressor Protein p27kip1 in Mediating Antitumor Activities in Response to Proteasome Inhibition
- (2008) Irina Nickeleit et al. CANCER CELL
- Thymoproteasome: probable role in generating positively selecting peptides
- (2008) Shigeo Murata et al. CURRENT OPINION IN IMMUNOLOGY
- Mechanisms of proteasome inhibitor action and resistance in cancer
- (2008) David J. McConkey et al. DRUG RESISTANCE UPDATES
- Distinct Specificities ofMycobacterium tuberculosisand Mammalian Proteasomes forN-Acetyl Tripeptide Substrates
- (2008) Gang Lin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism
- (2008) Michael Groll et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More